Genprex Receives Israeli Patent for Reqorsa® Gene Therapy in Combination with PD-1 Antibodies

On April 30, 2026, Genprex, Inc. announced that the Israel Patent Office (ILPO) has granted a new patent covering the use of its lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), in combination with PD-1 antibodies for the treatment of cancer. This strategic expansion of the company's intellectual property portfolio builds upon previously granted patents for the same combination therapy in major global markets, including the U.S., Europe, China, Japan, and several others. REQORSA is currently being developed primarily for the treatment of lung cancer in combination with approved targeted therapies and immunotherapies. Preclinical data suggests that REQORSA is complementary to these existing treatments. The company highlighted the significant clinical need in Israel, where lung cancer remains the leading cause of cancer-related deaths. While the filing focuses on the patent grant, Genprex continues to advance its clinical development programs in oncology and diabetes, though it remains subject to risks regarding regulatory approvals and long-term liquidity needs.